Clinical Trial Update: Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of a Rituximab, Fludarabine, Cyclophosphamide, and Yttrium-90 ibritumomab tiuxetan regimen in relapsed B-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Rituximab (Rituxan) (rituximab)
• ibritumomab tiuxetan (Zevalin) (ibritumomab tiuxetan)

Snippet

Sponsor: Technical University of Munich | Conditions: Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN